Fundz

Arbutus

Warminster, Pennsylvania, United States · Biopharma, Biotechnology, Healthcare

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing

Key facts

Headquarters
Warminster, Pennsylvania, United States
Employees
Unknown
Industries
Biopharma, Biotechnology, Healthcare
Status
Public (ABUS)
Website
www.arbutusbio.com
LinkedIn
Company page

Recent activity at Arbutus

  • : SEC 8-K (8.01): On November 12, 2026, Arbutus Biopharma Corporation posted an updated corporate presentation on its website, reflecting potential new strategic directions or updates on their business operations. This presentation is significant for stakeholders as it may contain insights into the company's future plans or performance metrics. A copy of this presentation is included as Exhibit 99.1 in the filing, suggesting its importance for shareholder communications and engagement. This event pertains to the disclosure of ongoing corporate activities that could influence investor perception and market behavior.
  • : SEC 8-K (8.01): On October 22, 2026, Arbutus Biopharma Corporation announced via a press release that the U.S. Food and Drug Administration has lifted the clinical hold on its Investigational New Drug application for AB-101, an oral PD-L1 inhibitor. This significant development allows the Company to proceed with clinical trials for AB-101, which is expected to advance its drug development pipeline. The press release also details the implications for the Company's research and potential market positioning moving forward, indicating strategic importance in the competitive landscape of immune-oncology.
  • : SEC 8-K (8.01): On August 21, 2026, Arbutus Biopharma Corporation announced plans to launch a modified 'Dutch auction' tender offer to purchase up to US$230 million in value of its common shares, with a price range set between US$5.00 and US$5.75 per share. The tender offer has not yet commenced, and the company has indicated that there are no assurances it will proceed under the terms outlined. This announcement is significant for shareholders as it represents an opportunity for them to sell their shares back to the company at a predetermined range, potentially impacting share liquidity and overall market sentiment. The official commencement date of the tender offer will trigger additional regulatory filings with the SEC and Canadian authorities.
  • : SEC 8-K (5.02):
  • : SEC 8-K (5.02): On May 26, 2026, Arbutus Biopharma Corporation held its Annual General and Special Meeting of Shareholders where shareholders approved the 2026 Omnibus Share and Incentive Plan, which replaces the previous 2011 and 2016 plans. This plan authorizes the issuance of 16,300,000 common shares. Additionally, shareholders elected the board's nominees for directors and approved the compensation of named executive officers. Notably, Ernst & Young LLP was appointed as the independent registered public accounting firm for 2026. The event's significance lies in the strategic shift in the company's incentive structure designed to align better with shareholder interests and corporate goals.
  • : SEC 8-K (8.01): On April 15, 2026, Arbutus Biopharma Corporation announced that the U.S. FDA granted Fast Track designation for imdusiran, a treatment for chronic hepatitis B. This designation aims to expedite the development and review of therapies addressing serious conditions with unmet medical needs. The press release highlights the importance of this designation for the potential advancement of imdusiran, which could significantly enhance treatment options for patients suffering from chronic hepatitis B.
  • : SEC 8-K (1.01): On March 3, 2026, Arbutus Biopharma Corporation, Genevant Sciences GmbH, and Moderna, Inc. entered into a Settlement Agreement aimed at resolving patent infringement litigation pertaining to Moderna's unauthorized use of Arbutus/Genevant's lipid nanoparticle delivery technology. Key terms of the agreement include a noncontingent payment of $950 million to Arbutus/Genevant by July 8, 2026, alongside potential additional contingent payments totaling up to $1.3 billion depending on the outcome of appeals related to claims under 28 U.S.C. §1498. This settlement effectively concludes ongoing legal disputes over Moderna's vaccine technologies, including Spikevax, and may have significant financial and operational implications for both parties involved.
  • : SEC 8-K (8.01): On February 17, 2026, the U.S. District Court for the District of Delaware issued a memorandum and order regarding the litigation between Arbutus Biopharma Corporation and its licensee Genevant Sciences GmbH against Moderna Inc. This litigation seeks damages for the infringement of several U.S. Patents related to Moderna's COVID-19 vaccine, MRNA-1273. The court's ruling addressed motions for summary judgment and the exclusion of expert testimony. This significant legal development could impact the ongoing business operations of both Arbutus and Moderna, particularly concerning patent protections and potential financial liabilities.
  • : SEC 8-K (8.01): On February 17, 2026, Arbutus Biopharma Corporation, alongside its licensee Genevant Sciences GmbH, received a ruling from the U.S. District Court for the District of Delaware regarding their litigation against Moderna Inc. This case involves claims of patent infringement concerning multiple U.S. Patents related to Moderna's COVID-19 vaccine, mRNA-1273. The ruling addressed various motions, including those for summary judgment and to exclude expert testimony. This development is significant as it could impact the ongoing legal landscape surrounding vaccine patent rights and may have financial implications for both parties involved.
  • : SEC 8-K (8.01):

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Arbutus funding history

DateRoundAmount
Dec 2021Venture$15.0M
Jun 2021Venture$81.0M

Leadership

  • William Collier, Executive Officer, Director
  • Frank Torti, Director
  • Daniel Burgess, Director
  • Richard Henriques, Director
  • Keith Manchester, Director
  • Eric Venker, Director
  • James Meyers, Director
  • Andrew Cheng, Director
  • Tram Tran, Director
  • Zhengbin Yao, Executive Officer, Director
  • Michael McElhaugh, Chief Executive Officer
  • Karen Sims, Chief Medical Officer

Verified email and direct lines for Arbutus’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Arbutus in the news

Companies similar to Arbutus

About Arbutus: questions and answers

What does Arbutus do?

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing

Where is Arbutus headquartered?

Arbutus is headquartered in Warminster, Pennsylvania, United States.

Has Arbutus raised funding?

Yes. Fundz has recorded 2 funding events for Arbutus. The most recent, $15.0M, was in Dec 2021.

Who leads Arbutus?

Michael McElhaugh is a Chief Executive Officer at Arbutus.

What is the latest news on Arbutus?

On Nov 13, 2025, SEC 8-K (8.01): On November 12, 2026, Arbutus Biopharma Corporation posted an updated corporate presentation on its website, reflecting potential new strategic directions or updates on their business operations. This presentation is significant for stakeholders as it may contain insights into the co

Is Arbutus a public company?

Yes. Arbutus is publicly traded under the ticker ABUS.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Arbutus across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.